Hi, I have just been think about the recent announcement by sight sciences they are going to publish study data (which we expect to meet MACs criteria EVEN if they don’t change their proposal)
So leading upto this MACs proposed change we were in the situation - a possibility of the change being supported - a high probability of it impacting revenue
since the change has been endorsed, we have - a possibility of it being appealed - becoming more probable since they have deferred the date
what I’m trying to work out is whether we care at all any more, IF - it’s a FACT that sight sciences are about to release data which meets tye revised reimbursement criteria in any case - if it’s a FACT that this is not device specific and so covers iTrack advance also (or is this a probability?)
if both of these are true surely we’re good to go and keep growing revenue, but at the same time massively discounted shareprice since the whole MACS discussion started.
feel free to point out what I’m missing. It’s certainly a FACT that sight sciences insiders have been massively buying and maybe because as per above they knew their study data made the LCD decision irrelevant?
EYE Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)